Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cencora Biosimilars Chiefs Talk Adalimumab Pricing, Interchangeability And The IRA

Executives From Former AmerisourceBergen Firm Discuss Latest US Biosimilars Developments

Executive Summary

With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts